Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
127.57
+0.40 (0.31%)
Nov 13, 2026, 4:00 PM EST - Market closed
Kymera Therapeutics Stock Forecast
Stock Price Forecast
According to 24 analysts polled by S&P Global, Kymera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $145.22. The average 1-year stock price forecast is 13.84% higher than the current stock price, while the lowest is $116 (-9.07%) and the highest is $180 (+41.10%).
Price Target: $145.22 (+13.84%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 17 | 17 | 17 | 17 |
| Buy | 5 | 4 | 4 | 4 | 5 | 5 |
| Hold | 1 | 3 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 24 | 24 | 23 | 24 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $129 | Buy | Reiterates | $129 | +1.12% | Nov 3, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Maintains $130 → $140 | Buy | Maintains | $130 → $140 | +9.74% | Nov 2, 2026 |
| BTIG | BTIG | Buy Maintains $139 | Buy | Maintains | $139 | +8.96% | Nov 2, 2026 |
| Barclays | Barclays | Buy Maintains $139 → $170 | Buy | Maintains | $139 → $170 | +33.26% | Nov 2, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $146 → $150 | Buy | Reiterates | $146 → $150 | +17.58% | Oct 30, 2026 |
Financial Forecast
Revenue This Year
99.39M
from 39.21M
Increased by 153.48%
Revenue Next Year
42.03M
from 99.39M
Decreased by -57.72%
EPS This Year
-3.93
from -3.69
EPS Next Year
-5.12
from -3.93
EPS and Forward PE are based on non-GAAP adjusted numbers.